The round positions Semma to start learning whether its insulin-producing cells can control blood sugar levels in Type 1 diabetics. 

Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.

The series C, which moves Codiak’s total haul up toward $170 million, tees the biotech up to move its lead candidate into clinical trials.

The series A positions the startup, Mavupharma, to further its work on the use of oral STING modulators to treat cancer and infectious diseases.

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.

Using tech licensed from Yale University, Inozyme Pharma has emerged from stealth with $49 million and a mission.

Locus Biosciences is moving ahead with a first clinical trial for its CRISPR-based antimicrobial drugs—armed with $19 million in series A funding.

Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.